Cargando…

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis

Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fei, Zhang, Yiyin, Jia, Zhenya, Wu, Hongyang, Gu, Kangsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/
https://www.ncbi.nlm.nih.gov/pubmed/31205551
http://dx.doi.org/10.7150/jca.28896
_version_ 1783423779987259392
author Zhang, Fei
Zhang, Yiyin
Jia, Zhenya
Wu, Hongyang
Gu, Kangsheng
author_facet Zhang, Fei
Zhang, Yiyin
Jia, Zhenya
Wu, Hongyang
Gu, Kangsheng
author_sort Zhang, Fei
collection PubMed
description Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) was searched. Only phase II or III randomized controlled trials (RCTs) comparing the effectiveness and safety between oxaliplatin-based and cisplatin-based regimens as first-line treatment for advanced GC were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. The primary endpoints were complete remission rate (CRR), partial remission rate (PRR), objective response rate (ORR), and disease control rate (DCR). The second endpoint was the toxicity response. Results: 2,140 patients from six phase II or III RCTs were included. Compared to cisplatin-based therapy, subjects who received oxaliplatin-based treatment had significantly higher PRR (OR: 1.25, 95%CI: 1.05-1.48, P=0.01, I(2)=0%), ORR (OR: 1.21, 95%CI: 1.02-1.44, P=0.03, I(2)=0%) and DCR (OR: 1.76, 95%CI: 1.31-2.38, P=0.0002, I(2)=25%), but not CRR (OR: 0.70, 95%CI: 0.37-1.31, P=0.27, I(2)=0%). In addition, oxaliplatin-based therapy significantly decreased all grades of leukopenia, neutropenia, anemia, febrile neutropenia, nausea, stomatitis, creatinine elevation and thromboembolism, as well as grades 3-4 of leukopenia, neutropenia, anemia and febrile neutropenia than cisplatin-based regimen. However, oxaliplatin-based treatment strikingly increased the risk of thrombocytopenia, sensory neuropathy, diarrhea, fatigue and liver dysfunction. Conclusions: Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced GC, and is associated with less toxicity and better tolerability.
format Online
Article
Text
id pubmed-6547983
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-65479832019-06-14 Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis Zhang, Fei Zhang, Yiyin Jia, Zhenya Wu, Hongyang Gu, Kangsheng J Cancer Research Paper Background: This study was initially designed to examine whether oxaliplatin-based regimen was superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer (GC). Methods: Literature in EMBASE, PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) was searched. Only phase II or III randomized controlled trials (RCTs) comparing the effectiveness and safety between oxaliplatin-based and cisplatin-based regimens as first-line treatment for advanced GC were selected. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. The primary endpoints were complete remission rate (CRR), partial remission rate (PRR), objective response rate (ORR), and disease control rate (DCR). The second endpoint was the toxicity response. Results: 2,140 patients from six phase II or III RCTs were included. Compared to cisplatin-based therapy, subjects who received oxaliplatin-based treatment had significantly higher PRR (OR: 1.25, 95%CI: 1.05-1.48, P=0.01, I(2)=0%), ORR (OR: 1.21, 95%CI: 1.02-1.44, P=0.03, I(2)=0%) and DCR (OR: 1.76, 95%CI: 1.31-2.38, P=0.0002, I(2)=25%), but not CRR (OR: 0.70, 95%CI: 0.37-1.31, P=0.27, I(2)=0%). In addition, oxaliplatin-based therapy significantly decreased all grades of leukopenia, neutropenia, anemia, febrile neutropenia, nausea, stomatitis, creatinine elevation and thromboembolism, as well as grades 3-4 of leukopenia, neutropenia, anemia and febrile neutropenia than cisplatin-based regimen. However, oxaliplatin-based treatment strikingly increased the risk of thrombocytopenia, sensory neuropathy, diarrhea, fatigue and liver dysfunction. Conclusions: Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced GC, and is associated with less toxicity and better tolerability. Ivyspring International Publisher 2019-04-25 /pmc/articles/PMC6547983/ /pubmed/31205551 http://dx.doi.org/10.7150/jca.28896 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhang, Fei
Zhang, Yiyin
Jia, Zhenya
Wu, Hongyang
Gu, Kangsheng
Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title_full Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title_fullStr Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title_full_unstemmed Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title_short Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
title_sort oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: a meta-analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/
https://www.ncbi.nlm.nih.gov/pubmed/31205551
http://dx.doi.org/10.7150/jca.28896
work_keys_str_mv AT zhangfei oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis
AT zhangyiyin oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis
AT jiazhenya oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis
AT wuhongyang oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis
AT gukangsheng oxaliplatinbasedregimenissuperiortocisplatinbasedregimenintumourremissionasfirstlinechemotherapyforadvancedgastriccancerametaanalysis